By Professor Michelle Haber

Preprints

Han JZR; Phimmachanh M; Hastings JF; Leong KH; Ng BH; Ni J; Fontaine-Titley A; Cadell AL; O’Donnell YEI; Clearwater M; Kamili A; Haber M; Norris M; Timpson P; Trahair TN; Fletcher JI; Fey D; Kolch W; Latham SL; Croucher DR, 2025, Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma, http://dx.doi.org/10.1101/2025.04.26.650760

Azfar M; Gao W; Van den Haute C; Xiao L; Karsa M; Pandher R; Ronca E; Bongers A; Karsa A; Spurling D; Guo X; Mayoh C; Burns MR; Verhelst SHL; Norris MD; Haber M; Vangheluwe P; Somers K, 2024, The polyamine transporter ATP13A3 mediates DFMO-induced polyamine uptake in neuroblastoma, http://dx.doi.org/10.1101/2024.02.20.581161

Fuentes-Bolanos N; Courtney E; Mayoh C; Warby M; Lau L; Wong-Erasmus M; Khuong-Quang D-A; Barahona P; Padhye B; El-Kamand S; Nunag S; Ajuyah P; Sherstyuk A; Altekoester A-K; Sullivan A; Poplawski N; Kiraly-Borri C; O’Sullivan S; Marfan H; Alli R; Curnow L; Bhatia K; Anazodo A; Trahair T; Mateos M; Hansford J; Dholaria H; Josephi-Taylor S; Moore A; Nicholls W; Gottardo N; Downie P; Khaw S-L; Tapp H; McCowage G; Dalla-Pozza L; Alvaro F; Wood P; Tyrrell V; Haber M; Cowley M; Ekert P; Marshall G; Kirk J; Tucker K; Pinese M; Ziegler D, 2024, Integrated germline and somatic molecular profiling to detect cancer predisposition has a high clinical impact in poor-prognosis paediatric cancer, http://dx.doi.org/10.1101/2024.08.08.24311493

Ziegler D; Lau L; Khuong-Quang D-A; Mayoh C; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester A-K; Fuentes-Bolanos N; Yeung V; Sullivan A; Diamond Y; Omer N; Jessop S; Battaglia L; Zhukova N; Cui L; Lin A; Gifford A; Fleuren E; Dalla-Pozza L; Moore A; Khaw S; Eisenstat D; Gottardo N; Wood P; Tapp H; Alvaro F; McCowage G; Nicholls W; Hansford J; Manoharan N; Kotecha R; Mateos M; Lock R; Tyrrell V; Haber M; Trahair T; Cowley M; Ekert P; Marshall G, 2023, Precision-guided treatment improves outcomes for children with high-risk cancers, http://dx.doi.org/10.21203/rs.3.rs-3376668/v1

Hu W; Hu W; Kumar A; Qi S; Sadras T; Casan J; Ma D; Brown L; Haber M; Voskoboinik I; Trapani J; Ekert P; Fareh M, 2022, Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions, http://dx.doi.org/10.21203/rs.3.rs-1714034/v1

Hu W; Kumar A; Qi S; Sadras T; Casan JML; Ma D; Brown L; Haber M; Voskoboinik I; Trapani J; Ekert P; Fareh M, 2022, Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions, http://dx.doi.org/10.1101/2022.06.22.497105

Nelson C; Rogers S; Roychoudhury K; Tan YS; Atkinson C; Sobinoff A; Tomlinson C; Hsu A; Lu R; Dray E; Haber M; Fletcher J; Cesare A; Hegde R; Pickett H, 2022, The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation, http://dx.doi.org/10.1101/2022.10.10.511510

Rokita JL; Rathi K; Cardenas M; Upton K; Jayaseelan J; Cross K; Pfeil J; Ritenour L; Modi A; Farrel A; Way G; Kendsersky N; Patel K; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm J; Marshall G; Tyrrell V; Kalletla K; Braun F; Qi L; Du Y; Zhang H; Lindsay H; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan A; Leraas K; Coppens S; Doddapaneni H; Momin Z; Zhang W; Sacks G; Hart L; Krytska K; Mosse Y; Gatto G; Sanchez Y; Greene C; Diskin S; Vaske OM; Haussler D; Gastier-Foster J; Kolb A; Gorlick R; Li X-N; Reynolds P; Kurmasheva R; Houghton P; Smith M; Lock R; Raman P; Wheeler D; Maris J, 2019, Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design, http://dx.doi.org/10.1101/566455

Back to profile page